<SEC-DOCUMENT>0001193125-23-118520.txt : 20230426
<SEC-HEADER>0001193125-23-118520.hdr.sgml : 20230426
<ACCEPTANCE-DATETIME>20230426161020
ACCESSION NUMBER:		0001193125-23-118520
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230426
DATE AS OF CHANGE:		20230426

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scilex Holding Co
		CENTRAL INDEX KEY:			0001820190
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-268607
		FILM NUMBER:		23849814

	BUSINESS ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303
		BUSINESS PHONE:		(650) 516-4310

	MAIL ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Scilex Holding Company/DE
		DATE OF NAME CHANGE:	20221117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vickers Vantage Corp. I
		DATE OF NAME CHANGE:	20200804
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d492133d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-268607</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT NO. 4 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
March&nbsp;17, 2023) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Scilex Holding Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 28,078,672 Shares of Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus supplement supplements the prospectus dated March&nbsp;17, 2023 (the &#147;Prospectus&#148;), which forms a
part of our registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (No. <FONT STYLE="white-space:nowrap">333-268607)</FONT> for which Post-Effective Amendment No.&nbsp;1 was filed with the Securities and Exchange Commission on
March&nbsp;13, 2023 and declared effective by the Securities and Exchange Commission on March&nbsp;17, 2023. This prospectus supplement is being filed to update and supplement the information in the Prospectus with the information contained in our
Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the Securities and Exchange Commission on April&nbsp;26, 2023 (the &#147;Current Report&#148;). Accordingly, we have attached the Current Report to this prospectus
supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Prospectus and this prospectus supplement relate to the resale from time to time of up to 28,078,672
shares of our common stock, par value $0.0001 per share (the &#147;Common Stock&#148;), by YA II PN, Ltd., a Cayman Islands exempt limited partnership (the &#147;Selling Securityholder&#148;). The shares included in the Prospectus and this
prospectus supplement consist of shares of Common Stock that we have issued or that we may, in our discretion, elect to issue and sell to the Selling Securityholder, from time to time, pursuant to a standby equity purchase agreement we entered into
with the Selling Securityholder on November&nbsp;17, 2022, as amended and restated on February&nbsp;8, 2023 (the &#147;A&amp;R Yorkville Purchase Agreement&#148;), in which the Selling Securityholder has committed to purchase from us, at our
direction, up to $500,000,000 of our Common Stock, subject to terms and conditions specified in the A&amp;R Yorkville Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#147;SCLX&#148;. On April&nbsp;25, 2023, the last
reported sales price per share of our Common Stock was $6.79. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus supplement updates and supplements the
information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction
with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>See the section entitled &#147;Risk Factors&#148; beginning on page&nbsp;15 of the Prospectus as well as risks and
uncertainties described under similar headings in any amendments or supplements to the Prospectus to read about factors you should consider before buying our securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these
securities or passed upon the accuracy or adequacy of this prospectus supplement or the Prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus supplement is April&nbsp;26, 2023 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 13 OR 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): April&nbsp;25, 2023 </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-39852</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">92-1062542</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>960 San Antonio Road, Palo Alto, California, 94303</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices, including zip code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (650)
<FONT STYLE="white-space:nowrap">516-4310</FONT> </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report) </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading<BR>Symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Common stock, par value $0.0001 per share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">SCLX</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">The Nasdaq Stock Market LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Warrants to purchase one share of common stock, each at an exercise price of $11.50 per share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">SCLXW</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">The Nasdaq Stock Market LLC</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Emerging growth company &#9746; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act. &#9744;
</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01. Regulation FD Disclosure. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Press Release </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the
Order (as defined below), Scilex Holding Company (the &#147;Company&#148;) issued a press release on April&nbsp;25, 2023, a copy of which is attached to this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> as Exhibit 99.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information under this Item 7.01 of this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> is being furnished and shall
not be deemed filed for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing. This report will not be deemed an
admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01. Other
Events. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously disclosed, the Company&#146;s majority stockholder, Sorrento Therapeutics, Inc. (&#147;Sorrento&#148;) and its
wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc. (together with Sorrento, the &#147;Debtors&#148;), commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code (the &#147;Bankruptcy Code,&#148; and such
cases, the &#147;Chapter 11 Cases&#148;) in the United States Bankruptcy Court for the Southern District of Texas (the &#147;Bankruptcy Court&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously disclosed, on or around January&nbsp;19, 2023, Sorrento distributed shares of the Company&#146;s common stock to Sorrento&#146;s
stockholders (the &#147;Distributed Stock&#148;), which were restricted from being further transferred until May&nbsp;11, 2023 (the <FONT STYLE="white-space:nowrap">&#147;Lock-up&#148;)</FONT> as reflected in a restrictive legend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;24, 2023, the Official Committee of Unsecured Creditors in the Chapter 11 Cases filed the <I>Official Committee of Unsecured
Creditors&#146; Emergency Motion to Extend the Application of the Automatic Stay to Continue the Restricted Trading Period for Shares of Scilex Stock Distributed to the Debtors&#146; Shareholders</I> (the &#147;Motion&#148;), seeking the Bankruptcy
Court&#146;s extension of the application of the automatic stay to continue the restricted trading period for the Distributed Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
April&nbsp;25, 2023, the Bankruptcy Court entered an order approving the relief requested in the Motion (the &#147;Order&#148;). As set forth in the Order, the Bankruptcy Court extended the <FONT STYLE="white-space:nowrap">Lock-up</FONT> period for
the Distributed Stock until September&nbsp;1, 2023 (or an otherwise earlier date to be determined, as set forth in the Order). Accordingly, as described in the Order, any shares of the Distributed Stock (including any such shares held by brokerage
firms) may not be sold, transferred or otherwise disposed of and the holders of Distributed Stock are prohibited from causing or encouraging any third party to do the same. This extension applies only to the Distributed Stock and does not apply to
any securities of Scilex held by Sorrento or any other Scilex securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has notified its transfer agent of the Order and
the extension of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> period and, in light of the Order, the restrictive legend on each share of Distributed Stock will be updated to read as follows:<I>&nbsp;</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE TRANSFERRED, PLEDGED, HYPOTHECATED, LOANED, ENCUMBERED OR OTHERWISE DISPOSED OF WITHOUT THE CONSENT
OF SCILEX HOLDING COMPANY (THE &#147;COMPANY&#148;) PRIOR TO SEPTEMBER&nbsp;1, 2023. A TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE SHALL BE DEEMED TO INCLUDE, WITHOUT LIMITATION, THE (A)&nbsp;SALE OR ASSIGNMENT OF, OFFER TO SELL,
CONTRACT OR AGREEMENT TO SELL, GRANT OF ANY OPTION TO PURCHASE OR OTHERWISE DISPOSE OF OR AGREEMENT TO DISPOSE OF, DIRECTLY OR INDIRECTLY, OR ESTABLISHMENT OR INCREASE OF A PUT EQUIVALENT POSITION OR LIQUIDATION WITH RESPECT TO OR DECREASE OF A CALL
EQUIVALENT POSITION WITHIN THE MEANING OF SECTION 16 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (THE &#147;EXCHANGE ACT&#148;), WITH RESPECT TO, ANY SECURITY OF THE COMPANY, (B)&nbsp;ENTRY INTO ANY SWAP OR OTHER ARRANGEMENT THAT TRANSFERS TO
ANOTHER, IN WHOLE OR IN PART, ANY OF THE ECONOMIC CONSEQUENCES OF OWNERSHIP OF ANY SECURITY OF THE COMPANY, WHETHER ANY SUCH TRANSACTION IS TO BE SETTLED BY DELIVERY OF SUCH SECURITIES, IN CASH OR OTHERWISE, AND (C)&nbsp;ENGAGEMENT, WHETHER DIRECTLY
OR INDIRECTLY, IN ANY (I) &#147;SHORT SALE&#148; (AS SUCH TERM IS DEFINED IN RULE 200 OF REGULATION SHO OF THE EXCHANGE ACT) OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE OR (II)&nbsp;HEDGING TRANSACTION, WHICH ESTABLISHES A NET SHORT POSITION
WITH RESPECT TO ANY SECURITIES OF THE COMPANY (INCLUDING THE COMMON STOCK OF THE COMPANY), WITH RESPECT TO EACH OF CLAUSES (I)&nbsp;AND (II) HEREOF, EITHER FOR THE HOLDER&#146;S OWN PRINCIPAL ACCOUNT OR FOR THE PRINCIPAL ACCOUNT OF ANY OTHER PERSON.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Statement Concerning Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> includes certain statements that are not historical facts but are
forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as &#147;believe,&#148;
&#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;expect,&#148; &#147;should,&#148; &#147;would,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;potential,&#148;
&#147;seem,&#148; &#147;seek,&#148; &#147;future,&#148; &#147;outlook,&#148; and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are
not limited to, statements regarding the extension of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> period or earlier expiration of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> period and (ii)&nbsp;the update of the restrictive legend
on the Distributed Stock. The Company&#146;s actual results or outcomes and the timing of certain events may differ significantly from those discussed in any forward-looking statements. These statements are based on various assumptions and on the
current expectations of the Company&#146;s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any
investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Actual events and circumstances are
difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including the
unpredictability of trading markets and whether a market will be established for the Company&#146;s common stock and those factors discussed in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2022 and any subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the Securities and Exchange Commission (the &#147;SEC&#148;), in each case under the heading &#147;Risk Factors,&#148; and
other documents of the Company filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional
risks that the Company presently does not know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements
reflect the Company&#146;s expectations, plans or forecasts of future events and views as of the date of this document. The Company anticipates that subsequent events and developments will cause its assessments to change. However, while the Company
may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company&#146;s assessments
as of any date subsequent to the date of this document. Accordingly, undue reliance should not be placed upon the forward-looking statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d) Exhibits. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated April&nbsp;25, 2023, entitled &#147;Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Notice that Sorrento&#146;s Bankruptcy Court has Extended the Lockup
Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend&#148;.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>104</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SCILEX HOLDING COMPANY</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jaisim Shah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Jaisim Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer&nbsp;&amp; President</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: April&nbsp;25, 2023 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g466902g0426041520054.jpg" ALT="LOGO">
<B> </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FOR IMMEDIATE RELEASE</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>April&nbsp;25, 2023</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Notice that
Sorrento&#146;s Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PALO ALTO, CALIFORNIA &#150; April</B><B></B><B>&nbsp;25, 2023 (GLOBE NEWSWIRE) -</B> Scilex Holding Company (Nasdaq: SCLX, &#147;Scilex&#148;) announced
that its majority stockholder, Sorrento Therapeutics, Inc.&nbsp;(OTC: SRNEQ, &#147;Sorrento&#148;) has issued a notice that Sorrento&#146;s bankruptcy court has extended the expiration of the restrictions on transfer on the shares of common stock of
Scilex that were distributed by Sorrento to its stockholders as a dividend on January&nbsp;19, 2023 (the &#147;Distributed Stock&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sorrento
Therapeutics, Inc. (OTC: SRNEQ, &#147;Sorrento&#148;), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that, in connection with its
ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas entered an order extending the expiration of the restrictions on transfer on the Distributed Stock from May&nbsp;11, 2023 to September&nbsp;1, 2023 (or an
otherwise earlier date to be determined, as set forth in the order). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, as described in the Bankruptcy Court&#146;s order, any shares of the
Distributed Stock (including any such shares held by brokerage firms) may not be sold, transferred or otherwise disposed of and the holders of Distributed Stock are prohibited from causing or encouraging any third party to do the same. This
extension applies only to the Distributed Stock and does not apply to any securities of Scilex held by Sorrento or any other Scilex securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
Scilex Holding Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing <FONT
STYLE="white-space:nowrap">non-opioid</FONT> pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and
ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, its novel, <FONT
STYLE="white-space:nowrap">non-opioid</FONT> product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex intends to submit a request to the FDA for a type D meeting for purposes of <FONT
STYLE="white-space:nowrap">pre-NDA</FONT> discussion with the FDA. Scilex targets indications with high unmet needs and large market opportunities with <FONT STYLE="white-space:nowrap">non-opioid</FONT> therapies for the treatment of patients with
moderate to severe pain.&nbsp;Scilex launched its first commercial product ZTlido<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> in October 2018, <FONT STYLE="white-space:nowrap">in-licensed</FONT> a commercial product Gloperba<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> in June 2022, and its third <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product Elyxyb<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> in April 2023. It is also developing its
late-stage pipeline, which includes a pivotal Phase 3 candidate, and one Phase 2 and one Phase 1 candidate.&nbsp;Its commercial product, ZTlido<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (lidocaine topical system) 1.8%, or ZTlido<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with post-herpetic neuralgia, which is a form of post-shingles
nerve pain.&nbsp;Scilex <FONT STYLE="white-space:nowrap">in-licensed</FONT> the exclusive right to commercialize Gloperba<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (colchicine USP) oral solution, an
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> prophylactic treatment for painful gout flares in adults, in the U.S. Scilex <FONT STYLE="white-space:nowrap">in-licensed</FONT> the exclusive rights to commercialize Elyxyb<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> (celecoxib oral solution) in the U.S. and Canada, the only <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ready-to-use</FONT></FONT> oral solution for the acute treatment of migraine, with or without aura, in adults. Scilex is planning to commercialize Gloperba<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and Elyxyb<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> in 2023 and is well-positioned to market and distribute the product. Scilex&#146;s three product candidates are <FONT
STYLE="white-space:nowrap">SP-102</FONT> (injectable dexamethasone sodium phosphate viscous gel product containing 10 mg dexamethasone), or SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, a Phase 3, novel, viscous gel formulation
of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, with FDA Fast Track status; <FONT STYLE="white-space:nowrap">SP-103</FONT> (lidocaine topical system) 5.4%, a Phase 2 study, <FONT
STYLE="white-space:nowrap">triple-strength</FONT> formulation of ZTlido<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, for the treatment of acute low back pain, with FDA Fast Track status; and
<FONT STYLE="white-space:nowrap">SP-104,</FONT> 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride <FONT STYLE="white-space:nowrap">(DBR-LDN)</FONT> Capsule, for the treatment of chronic pain, fibromyalgia that has completed multiple
Phase 1 trial programs and is expected to initiate Phase 2 trials in 2023. For further information regarding the <FONT STYLE="white-space:nowrap">SP-102</FONT> Phase 3 efficacy trial, see NCT identifier NCT03372161 &#150;&nbsp;<U>Corticosteroid
Lumbar Epidural Analgesia for Radiculopathy &#150; Full Text View &#150; ClinicalTrials.gov</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding Company is headquartered in Palo Alto,
California. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page | 1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain
forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section&nbsp;21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results
to differ materially from those projected. <FONT STYLE="white-space:nowrap">Forward-looking</FONT> statements include statements regarding any early expiration of the restrictions on transfer on the Distributed Stock, Scilex&#146;s long-term
objectives and commercialization plans, future opportunities for Scilex, Scilex&#146;s future business strategies, Scilex&#146;s current and prospective product candidates, planned clinical trials and preclinical activities and potential product
approvals, as well as the potential for market acceptance of any approved products and the related market opportunity; statements regarding ZTlido<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Gloperba<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, <FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>), <FONT
STYLE="white-space:nowrap">SP-103</FONT> or SP-104, if approved by the FDA; Scilex&#146;s development and commercialization plans; and Scilex&#146;s products, technologies and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Risks and uncertainties that could cause Scilex&#146;s actual results to differ materially and adversely from those expressed in our forward-looking
statements, include, but are not limited to: risks regarding the compliance by brokerage firms with the orders of the U.S. Bankruptcy Court for the Southern District of Texas regarding record and beneficial ownership of Scilex common stock received
by Sorrento&#146;s stockholders in connection with Sorrento&#146;s previously announced dividend; risks associated with the unpredictability of trading markets and whether a market will be established for Scilex&#146;s common stock; general
economic, political and business conditions; risks related to the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; the risk that the potential product candidates that Scilex develops may not progress through clinical development or
receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex&#146;s product candidates; the risk that Scilex will be unable to successfully market or gain market
acceptance of its product candidates; the risk that Scilex&#146;s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their
willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the results of the Phase 2 trial for <FONT STYLE="white-space:nowrap">SP-103</FONT> or Phase 1 trials for
<FONT STYLE="white-space:nowrap">SP-104</FONT> may not be successful; risks that the prior results of the clinical trials of <FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>), <FONT
STYLE="white-space:nowrap">SP-103</FONT> or <FONT STYLE="white-space:nowrap">SP-104</FONT> may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks set forth in
Scilex&#146;s filings with the SEC. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in
this press release except as may be required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and Media </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding Company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">960 San Antonio Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94303 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office: (650) <FONT STYLE="white-space:nowrap">516-4310</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: investorrelations@scilexholding.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Website:
<U>www.scilexholding.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SEMDEXA<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> <FONT STYLE="white-space:nowrap">(SP-102)</FONT> is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA
is planned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ZTlido<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark owned by Scilex Pharmaceuticals Inc., a
wholly-owned subsidiary of Scilex Holding Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gloperba<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is the subject of an exclusive,
transferable license to use the registered trademark by Scilex Holding Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is the
subject of an exclusive, transferable license to use the trademark by Scilex Holding Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All other trademarks are the property of their respective
owners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:75%; vertical-align:top">&copy;</SUP> 2023 Scilex Holding Company All Rights Reserved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page | 2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g466902g0426041520054.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g466902g0426041520054.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% 1H# 2(  A$! Q$!_\0
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M.EM?7SG&=L<:_>D;T%<)"/'?C>/[7'=+HFF2<Q*K%7<>N1\Q^N0/2LK7Y_\
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MNN\5?\DUN?\ KUC_ )K7(_&#_D(Z7_UR?^8KK_%7_)-;G_KUC_FM &/\(?\
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MQ_VOY_7KZ'7FGC_P,TI?7-'0K<)\\\*<%N^]??U'X]>H!Z4S*BEF("@9))X
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MHN1S5.[UJ\L/$EP&5I=/C5/- ',>0/F'X_SH Z*:UM[@@SP12D="Z!L?G4@
M     Z 5BZ5?2W6O:K'Y_F6\8B,(&, ,N>/K4!FO-8U>\MHKM[.TM"%8Q ;W
M8Y[GIT- &Y+:V]P09K>*0CH70'^=1_V98?\ /C;?]^E_PJIHTL;&:./5A?JN
M",D%DZ]2.N:U: *O]F6'_/C;?]^E_P *GBBC@39%&D:#^%% %<_%+>Z[J5XD
M=[):6=J_E 0X#NPZDD_3]:V+*WGM(9%N+M[D Y1G4!@,=#CK0!)+9VL[;IK:
M&1O5T!/ZTS^S+#_GQMO^_2_X5B:<;[Q#$]\VH36L!<K#%!@8 [L>]6]%O[E[
MV]TV\<2S6A&)@,;U/3(]>GYT :']F6'_ #XVW_?I?\*?'8VD+AXK6!''1EC
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M&P1JV_RS+M^79U\S\O\ /:NCCMRD2(T\KLJ@%B>6]Z )Z*** "BBB@ HHHH
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..WE>7M]\YSFM6BB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
